Men (aged 40-49 years) with a single baseline prostate-specific antigen below 1.0 ng/mL have a very low long-term risk of prostate cancer: Results from a prospectively screened population cohort

Urology

Volumn 82, Issue 6, 2013, Pages 1211-1217

  Weight, Christopher J ^a   Kim, Simon P ^b   Jacobson, Debra J ^b   McGree, Michaela E ^b   Karnes, R Jeffrey ^b   St Sauver, Jennifer ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RISK; COHORT ANALYSIS; DIGITAL RECTAL EXAMINATION; FOLLOW UP; HIGH RISK PATIENT; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; PHYSICAL EXAMINATION; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; SCREENING TEST;

ADULT; COHORT STUDIES; DIGITAL RECTAL EXAMINATION; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; ROC CURVE; TREATMENT OUTCOME;

EID: 84888643698     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2013.06.074     Document Type: Article

References (27)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Onoclogy. Prostate Cancer Early Detection, version 2.2012. Available at: http://www.nccn.org/professionals/physician-gls/pdf/prostate-detection.pdf. Accessed March 27, 2013.
2. O.W. Brawley, D.P. Ankerst, and I.M. Thompson Screening for prostate cancer CA Cancer J Clin 59 2009 264 273
3. O.W. Brawley, and T. Gansler Introducing the 2010 American Cancer Society prostate cancer screening guideline CA Cancer J Clin 60 2010 68 69
4. Carter HB, Albertsen P, Barry MJ, et al. American Urological Association. Early detection of prostate Cancer: AUA guideline. Available at: http://www.auanet.org/common/pdf/education/clinical-guidance/ Prostate-Cancer-Detection.pdf. Accessed May 31, 2013.
5. R. Chou Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force Ann Intern Med 2011
6. F.H. Schroder, J. Hugosson, and M.J. Roobol Prostate-cancer mortality at 11 years of follow-up N Engl J Med 366 2012 981 990
7. J.A. Hanley Measuring mortality reductions in cancer screening trials Epidemiol Rev 33 2011 36 45
8. G.L. Andriole, E.D. Crawford, and R.L. Grubb 3rd Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up J Natl Cancer Inst 104 2012 125 132
9. A.S. Whittemore, C. Lele, G.D. Friedman, T. Stamey, J.H. Vogelman, and N. Orentreich Prostate-specific antigen as predictor of prostate cancer in black men and white men J Natl Cancer Inst 87 1995 354 360
10. F.H. Schroeder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
11. J. Fang, E.J. Metter, and P. Landis Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging Urology 58 2001 411 416
12. S. Loeb, K.A. Roehl, and J.A.V. Antenor Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old Urology 67 2006 316 320
13. D. Ulmert, A.M. Cronin, and T. Björk Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study BMC Medicine 6 2008 6 14
14. A.S. Whittemore, P.M. Cirillo, D. Feldman, and B.A. Cohn Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of black and white Americans J Urol 174 2005 872 876
15. H. Lilja Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50 Cancer 117 2011 1210 1219
16. H. Lilja, D. Ulmert, and T. Bjork Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years J Clin Oncol 25 2007 431 436
17. J.E. Oesterling, S.J. Jacobsen, and C.G. Chute Serum prostate-specific antigen in a community-based population of healthy men: Establishment of age-specific reference ranges JAMA 270 1993 860 864
18. H.G. Welch, and P.C. Albertsen Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005 J Natl Cancer Inst 101 2009 1325 1329
19. M.J. Roobol, D.W. Roobol, and F.H. Schröder Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam) Urology 65 2005 343 346
20. K.L. Greene, P.C. Albertsen, and R.J. Babaian Prostate Specific Antigen Best Practice Statement: 2009 Update J Urol 182 2009 2232 2241
21. A. Bill-Axelson, L. Holmberg, and M. Ruutu Radical prostatectomy versus watchful waiting in early prostate cancer N Engl J Med 364 2011 1708 1717
22. T.J. Wilt, M.K. Brawer, and K.M. Jones Radical prostatectomy versus observation for localized prostate cancer N Engl J Med 367 2012 203 213
23. A.J. Vickers, and H. Lilja We need a better marker for prostate cancer. How about renaming PSA? Urology 2011
24. G.L. Andriole, R.L. Grubb, and S.S. Buys Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 2009 1310 1319
25. J. Mohler, R.R. Bahnson, and B. Boston Prostate cancer: clinical practice guidelines in oncology™ J Natl Compr Canc Netw 8 2010 162 200
26. Surveillance Epidemiology and End Results. Prostate Cancer SEER Incidence and U.S. Death Rates, Age-Adjusted and Age-Specific Rates, by Race. Available at: http://seer.cancer.gov/csr/1975-2009-pops09/browse-csr.php?section= 23&page=sect-23-table.07.html. Accessed November 5, 2012.
27. A.J. Vickers, and H. Lilja Predicting prostate cancer many years before diagnosis: how and why? World J Urol 30 2011 131 135